CNTX Context Therapeutics Inc.
Legal ·
The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000.
Nasdaq gave Context Therapeutics until February 23, 2026 to regain compliance with the $1.00 minimum bid price rule. The company says it may need a reverse stock split and cannot promise it will regain compliance.
The new deadline is February 23, 2026. The company says a reverse stock split is an option if needed, and it gives no assurance it will regain compliance by then.
The shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.
Context Therapeutics is a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, a CLDN6 x CD3 TCE that the company says is highly selective for CLDN6 over related claudins and may reach tumors with low, medium or high CLDN6 expression. CTIM-76 is in a Phase 1 dose escalation and expansion trial in patients with CLDN6-positive gynecologic and testicular cancers, with the first patient dosed in January 2025. CT-95, a mesothelin x CD3 TCE, is also in Phase 1, with the first patient dosed in April 2025. CT-202, a Nectin-4 x CD3 pH-dependent TCE designed to be preferentially active within the tumor microenvironment, had its first-in-human application submitted to an Australian ethics committee in March 2026. The company expects to dose the first patient in the CT-202 Phase 1 trial in the third quarter of 2026.
| Product or program | What it is | Stage |
|---|---|---|
| CTIM-76 | CLDN6 x CD3 T cell engaging bispecific antibody for solid tumors | Phase 1; first patient dosed January 2025 |
| CT-95 | Mesothelin x CD3 T cell engaging bispecific antibody | Phase 1; first patient dosed April 2025 |
| CT-202 | pH-dependent Nectin-4 x CD3 T cell engaging bispecific antibody | first patient dosing expected in the third quarter of 2026 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $31.9 million | $22.7 million |
| Net income (loss) | -$36.1 million | -$26.7 million |
| Cash from operations | -$26.4 million | -$14.6 million |
| Cash and equivalents | $66.0 million | $94.4 million |
Our latest story on this, dated Sep 2, 2025: "Context Therapeutics gets Nasdaq extension to February 23, 2026 on minimum bid price rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 5, 2026: "Context Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid". The story links the filing or release it is based on. Read the story.
Context Therapeutics Inc. trades under the ticker CNTX on NASDAQ.
Context Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6K9; LS:A3CWBU; LSX:A3CWBU.
The SEC Central Index Key (CIK) for Context Therapeutics Inc. is 1842952. Its filings are on SEC EDGAR.
91,879,177 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Context Therapeutics Inc. under United States.
Our directory classifies Context Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Context Therapeutics Inc. is US21077P1084.
aibio.space lists Context Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Context Therapeutics is a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, a CLDN6 x CD3 TCE that the company says is highly selective for CLDN6 over related claudins and may reach tumors with low, medium or high CLDN6 expression.
CTIM-76: CLDN6 x CD3 T cell engaging bispecific antibody for solid tumors Stage: Phase 1; first patient dosed January 2025.
CT-95: Mesothelin x CD3 T cell engaging bispecific antibody Stage: Phase 1; first patient dosed April 2025.
Context Therapeutics Inc. reported a net loss of $36.1 million for the fiscal year ended Dec 31, 2025, and used $26.4 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio